These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33782049)

  • 1. Randomized Controlled Trial of the Gastrin/CCK
    Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
    Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
    Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
    Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
    Boyce M; Warrington S; Black J
    Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
    Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
    Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo.
    Obszynska JA; Atherfold PA; Nanji M; Glancy D; Santander S; Graham TA; Otto WR; West K; Harrison RF; Jankowski JA
    Gut; 2010 Feb; 59(2):156-63. PubMed ID: 19651631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
    Boyce M; Warrington S
    Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial of the effect of a gastrin/CCK
    Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
    Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus.
    Lee Y; Urbanska AM; Hayakawa Y; Wang H; Au AS; Luna AM; Chang W; Jin G; Bhagat G; Abrams JA; Friedman RA; Varro A; Wang KK; Boyce M; Rustgi AK; Sepulveda AR; Quante M; Wang TC
    Oncotarget; 2017 Jan; 8(1):203-214. PubMed ID: 27448962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor.
    Haigh CR; Attwood SE; Thompson DG; Jankowski JA; Kirton CM; Pritchard DM; Varro A; Dimaline R
    Gastroenterology; 2003 Mar; 124(3):615-25. PubMed ID: 12612900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus.
    Sreedharan L; Mayne GC; Watson DI; Bright T; Lord RV; Ansar A; Wang T; Kist J; Astill DS; Hussey DJ
    World J Gastroenterol; 2017 Aug; 23(30):5508-5518. PubMed ID: 28852310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus.
    Wang JS; Varro A; Lightdale CJ; Lertkowit N; Slack KN; Fingerhood ML; Tsai WY; Wang TC; Abrams JA
    Am J Gastroenterol; 2010 May; 105(5):1039-45. PubMed ID: 19904251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.
    Alnasser S; Agnihotram R; Martel M; Mayrand S; Franco E; Ferri L
    Can J Surg; 2019 Apr; 62(2):93-99. PubMed ID: 30907564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosa-Associated Microbiota in Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma Differ Similarly Compared With Healthy Controls.
    Peter S; Pendergraft A; VanDerPol W; Wilcox CM; Kyanam Kabir Baig KR; Morrow C; Izard J; Mannon PJ
    Clin Transl Gastroenterol; 2020 Aug; 11(8):e00199. PubMed ID: 32955191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.
    Levine DS; Haggitt RC; Blount PL; Rabinovitch PS; Rusch VW; Reid BJ
    Gastroenterology; 1993 Jul; 105(1):40-50. PubMed ID: 8514061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
    Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
    J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
    Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
    Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
    Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretory Phospholipase A
    Gergen AK; Jarrett MJ; Li A; White AM; Meng X; Fullerton DA; Weyant MJ
    J Surg Res; 2021 Mar; 259():562-568. PubMed ID: 33261858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced Neoplasia.
    Neyaz A; Odze RD; Rickelt S; Nieman LT; Bledsoe JR; Mahadevan KK; Arora K; Jeck WR; Taylor MS; Gala M; Patil DT; Yilmaz OH; Rivera MN; Ting DT; Deshpande V
    Clin Transl Gastroenterol; 2020 Dec; 12(1):e00272. PubMed ID: 33464729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.